SCM
PMVP icon

Silverarc Capital Management’s PMV Pharmaceuticals PMVP Stock Holding History

Silverarc Capital Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-550,000
Closed -$1.71M – 92
2023
Q4 		$1.71M Buy
+550,000
New +$1.46M 0.51% 51

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Silverarc Capital Management's PMVP Position: Q1 2024 in Review

Silverarc Capital Management sold out of PMV Pharmaceuticals (PMVP) in Q1 2024, closing a stake of 550,000 shares — an estimated $1.71M sold.

Silverarc Capital Management first reported a position in PMVP in Q4 2023 and held it in 1 quarter. The position peaked at $1.71M in Q4 2023. 99 funds tracked by Wall St. Rank hold PMVP as of Q1 2024.

  • Silverarc Capital Management reported no remaining PMV Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 550,000 PMV Pharmaceuticals shares in Q1 2024, an estimated $1.71M.
  • Silverarc Capital Management first reported a position in PMV Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Silverarc Capital Management's PMV Pharmaceuticals position peaked at $1.71M in Q4 2023.
  • 99 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2024.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.